# A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

> **NCT02124148** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 167 (actual)

## Conditions studied

- Neoplasm Metastasis
- Colorectal Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** Prexasertib
- **DRUG:** Cisplatin
- **DRUG:** Cetuximab
- **DRUG:** G-CSF
- **DRUG:** Pemetrexed
- **DRUG:** Fluorouracil
- **DRUG:** LY3023414
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT02124148
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-18
- **Primary completion:** 2020-02-13
- **Final completion:** 2020-02-13
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2020-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02124148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02124148, "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02124148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*